OncoMatch/Clinical Trials/NCT06492408
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
Is NCT06492408 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab for hepatic cancer.
Treatment: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab — This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by delivery of CTLA4 and PD1 or PDL1 antibodies combination through CT-guided intra-tumor (IT) injection.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: clinical trial therapy
Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks
Cannot have received: any prior malignancy
Patients accompanied with other tumors or past medical history of malignancy
Lab requirements
Blood counts
ANC >= 1.5 x 10^9/L; Hemoglobin >= 8.0 g/dL; Platelets >= 100 x 10^9/L
Kidney function
Creatinine <= 1.5 x ULN or calculated creatinine clearance >= 50 mL/min using Cockcroft-Gault formula OR 24-hour urine creatinine clearance >= 50 mL/min
Liver function
Total bilirubin <= 1.5 x ULN (except subjects with Gilbert syndrome who can have total bilirubin < 3.0 mg/dL)
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L; Hemoglobin >= 8.0 g/dL; Platelets >= 100 x 10^9/L; Total bilirubin <= 1.5 x upper limit of normal (ULN) (except subjects with Gilbert syndrome who can have total bilirubin < 3.0 mg/dL); Creatinine <= 1.5 x ULN or calculated creatinine clearance >= 50 mL/min using Cockcroft-Gault formula for creatinine clearance calculation OR 24-hour urine creatinine clearance >= 50 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06492408 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify